Mobilize the immune system to
fight cancer.
Streamlining T-cell engager development
with a diverse panel of fully human
CD3-binding antibodies.
ANTIBODY MEDICINES CAN BRIDGE THE GAP BETWEEN CANCER AND THE IMMUNE SYSTEM.
Natural immune systems fight cancer with tumor-killing T cells.
But cancer can hide.
CD3 T-cell engagers can:
Bring T cells and cancer cells close together by binding both targets at the same time.
Activate T cell cancer-killing functions by binding to a protein called CD3.
CD3 T-cell engagers have been hard to develop.
It’s hard to strike the right balance.
The CD3-binding arm needs to:
Activate tumor cell killing
Fine-tune cytokine production to limit
unwanted side-effects
It’s hard to find the perfect pair.
The tumor-binding arm needs to:
Specifically bind cancer targets and not healthy tissues
Allow for binding to T cells and cancer cells with the correct geometry
Development of a diverse panel of fully human
CD3-binding antibodies.
We used our integrated antibody discovery, characterization, and engineering technologies to develop hundreds of CD3-binding antibodies that are diverse, developable, and validated.
STREAMLINE T-CELL ENGAGER DEVELOPMENT.
By integrating our CD3 panel with our antibody discovery and engineering technology, we can rapidly discover T-cell engagers that strike the right balance.
